Novavax launches late-stage COVID-19 vaccine trial in UK
LONDON (UK) – Novavax Inc on Thursday initiated a late-stage trial of its experimental COVID-19 vaccine in the UK by partnering with the government’s Vaccines Taskforce. This has sent up the company’s shares to 6% after the bell.
The study is expected to take in 10,000 participants aged between 18 and 84 years. A small, early-stage clinical trial saw the vaccine candidate producing high levels of antibodies against the novel coronavirus.
Data from the trial will help regulatory submissions for license in the UK, EU and other countries. The company has previously announced that it is expecting to file for the vaccine’s US approval in December.
Novavax said that the trial will involve at least 25% of participants over the age of 65 and will prioritise groups most affected by the COVID-19.
It added that it could make up to 2 billion annualised doses, once the capacity required is made available online by mid-2021.
Britain recorded its highest number of daily COVID-19 cases on Thursday at 6,634.